Fuhui Ventures
富汇创投
Fuhui Ventures (富汇创投) is a Chinese venture capital firm that appears as a recurring co-investor alongside larger funds in biopharma and healthcare deals . Its portfolio activity visible in elsewhere's corpus clusters in 2020-2022: it followed Gaorong Capital into CASI Pharmaceuticals' Pre-A and Pre-A+ rounds for nuclear receptor and GPCR-targeted drug R&D, joined Gaorong and Qingsong Capital in ZhiXiang Biologics' over-500-million-yuan Series C for biologics CDMO capacity, and more recently backed Laimang Biotech's 50-million-yuan angel rounds for metabolic-enhanced CAR-T therapies alongside Tian Tu Investment and others . The pattern suggests a focus on early-to-growth stage life sciences, typically as a syndicate participant rather than lead. elsewhere's corpus does not cover its founding, AUM, or team.
AI-generated — may contain errors, please verify.
Coverage
5Y News | 5Y Capital Portfolio Company "Laimang Biotech" Raises 50 Million Yuan in New Funding
Accelerating the clinical translation of ultra-low-dose CAR-T.
CDMO firm ZhiXiang Biologics raises over 500 million yuan in Series C funding to accelerate biopharma R&D for global clients
A one-stop CDMO platform for biologics R&D and manufacturing.
Global SaaS, New Brands, and Biopharma Companies Close New Funding Rounds | Rongbao · February
The vitality of spring.
Dialogue with CASI's Huaqiang Xu: "Following Nature's Way" in Drug R&D | Gaorong "Future"
CasKedy announced the completion of a nearly RMB 100 million Pre-A+ funding round.
